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ABSTRACT  35 
Rifapentine is a rifamycin used to treat tuberculosis. As for rifampicin, plasma exposures of 36 
rifapentine are associated with treatment response. While concomitant food intake and HIV 37 
infection explain part of the pharmacokinetic variability associated with rifapentine, few 38 
studies have evaluated the contribution of genetic polymorphisms. We evaluated the effects 39 
of functionally significant polymorphisms of the genes encoding OATP1B1, PXR, CAR, and 40 
AADAC on rifapentine exposure. Two studies evaluating novel regimens amongst Southern 41 
African patients with drug-susceptible pulmonary tuberculosis were included in this analysis. 42 
In RIFAQUIN, rifapentine was administered in the continuation phase of antituberculosis 43 
treatment in 1200mg once-weekly or 900mg twice-weekly doses. In Daily-RPE  450 or 44 
600mg were given daily during the intensive-phase of treatment.  Nonlinear mixed-effects 45 
modelling was used to describe the pharmacokinetics of rifapentine and to identify significant 46 
covariates. A total of 1144 drug-concentration measurements, from 326 patients, were 47 
included in the analysis. Pharmacogenetic information was available for 162 patients. A one-48 
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compartment model with first-order elimination and transit compartment absorption 49 
described the data well. In a typical patient (body weight of 56kg, fat-free-mass of 45kg), the 50 
values of clearance and volume of distribution were 1.33L/h and 25L, respectively. Patients 51 
carrying the AA variant (65.4%) of AADAC rs1803155 were found to have 10.4% lower 52 
clearance. HIV+ infected patients had 21.9% lower bioavailability. Once weekly doses of 53 
1200 mg were associated reduced clearance (-13.2%), compared to more frequently 54 
administered doses. Bioavailability was 23.3% lower amongst patients participating in the 55 
Daily-RPE study compared to RIFAQUIN. This is the first study to report the effect of 56 
AADAC rs1803155AA on rifapentine clearance. The observed increase in exposure is modest 57 
and unlikely to be of clinical relevance. The difference in bioavailability between the two 58 
studies is probably related to the different food concomitant to the dose. HIV coinfected 59 
patients had lower rifapentine exposures. 60 
 61 
INTRODUCTION 62 
Rifamycins play a key role in the multidrug treatment of tuberculosis. Their sterilizing 63 
activity is exposure-dependent (1-3). Rifapentine, was approved by the Food and Drug 64 
Administration (FDA) in 1998 for the treatment of pulmonary tuberculosis (3,4). Rifapentine 65 
pharmacokinetics are influenced by age, weight, dosing pattern, human immunodeficiency 66 
virus (HIV) infection, and sex (5,6). Rifapentine is less rapidly absorbed than rifampicin, 67 
with peak plasma concentrations reached within 5 hours. Concomitant food markedly 68 
increases its absorption; the extent of rifapentine absorption increased by 33-86% when given 69 
with meals (7). Rifapentine has a half-life of approximately 12 hours in humans (8,9). With 70 
its long half-life and excellent sterilizing activity, rifapentine is an attractive alternative to 71 
rifampicin and is increasingly used to treat active tuberculosis and latent infection. However, 72 
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there is marked interpatient variability in rifamycin pharmacokinetics (10). The primary 73 
metabolic pathways for rifapentine involve deacetylation to the primary enzymatic metabolite 74 
25-desacetyl rifapentine, which is mediated by human arylacetamide deacetylase (AADAC) 75 
and non-enzymatic hydrolysis resulting in formation of the secondary metabolites 3-formyl 76 
rifapentine and 3-formyldesacetyl rifapentine (11). Protein binding of rifapentine is estimated 77 
to be about 98% (3,12). Like other rifamycin’s, rifapentine induces its own metabolism (9). 78 
Previously published data indicate that single nucleotide polymorphisms (SNPs) in the solute 79 
carrier organic anion transporter 1B1 (SLCO1B1) gene encoding the OATP1B1 80 
transmembrane receptor affect rifampicin concentrations (13,14). SLCO1B1 rs4149032 C>T 81 
polymorphism, found in 70% of South Africans with tuberculosis living in Cape Town, was 82 
associated with 20% and 28% reductions in rifampicin bioavailability in heterozygotes and 83 
homozygotes, respectively (14). Rifamycins are also substrates of the drug efflux pump P-84 
glycoprotein coded for by the polymorphic ABCB1 gene (15) and are metabolized mainly by 85 
polymorphic human arylacetamide deacetylase (AADAC) (16). Human rifamycin exposures 86 
are also modulated by the pregnane X receptor (PXR) and constitutive androstane (CAR) 87 
nuclear receptors (17). Since the development of resistance to rifamycins and their 88 
bactericidal effects are related to rifamycin concentrations, SNPs substantially influencing 89 
rifamycin concentrations may be of therapeutic importance. Little is known about the 90 
pharmacogenetic correlates of rifapentine pharmacokinetics, which may potentially help in 91 
finding the optimal dose of rifapentine. Therefore, the aim of this study was to determine the 92 
effect of polymorphisms of SLCO1B1, PXR, CAR, and AADAC on rifapentine 93 
pharmacokinetics. 94 
RESULTS 95 
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A total of 326 patients were included in the study and contributed a total of 1151 96 
concentrations-time points. Only 7 concentrations were below the LLOQ and were omitted 97 
from the analysis. The median body weight and age of the study participants were 56 kg and 98 
32 years respectively. All demographic characteristics are summarized in Table 1.  99 
The population pharmacokinetics of rifapentine was well described by a one-compartment 100 
model with first-order elimination and transit compartment absorption. Fat-free-mass(FFM) 101 
was found to be the best size descriptor for clearance (ΔOFV 93 points, p<0.001 when 102 
including FFM for allometric scaling on clearance and 23 points better than using body 103 
weight) and total body weight for volume of distribution (ΔOFV 20, p<0.001). The 104 
absorption of rifapentine was described using a series of transit compartments, which 105 
significantly improved the model with respect to simple first-order absorption (ΔOFV 421, 106 
p<0.001). In a typical patient (46 kg FFM and 56 kg weight), the values of clearance and 107 
volume of distribution were 1.33 L/h and 25 litres. Final parameter estimates (shown in Table 108 
3) were in agreement with the previously published results (6,18) and a VPC of the final 109 
model is shown in Figure 1.  110 
Of 326 patients, pharmacogenetic data was available for 162 (49.7%) all of whom were 111 
enrolled from South African sites. The distribution of genotype and allele frequencies are 112 
presented in Table 2.  SLCO1B1 rs2306283 and AADAC rs1803155 variant alleles were 113 
found in 82% of patients whereas the NR1I2 rs2472677 and NR1I2 rs1523130 variant alleles 114 
existed at a low overall frequency of 33.5% and 16.4% respectively. In keeping with our 115 
previous findings among South Africans in Cape Town (14), the SLCO1B1 rs4149032 variant 116 
allele frequency was found to be 0.75 (Table 2). 117 
After screening and inclusion of genetic information (and imputation of missing genotype 118 
with a mixture model), patients homozygous for AADAC rs1803155 AA polymorphism were 119 
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found to have 10.4% lower clearance of rifapentine compared to subjects that were 120 
rs1803155 GG or GA (ΔOFV 6.2, p=0.013). Initially the three categories of rs1803155 (AA, 121 
GA, GG) were analysed as separate groups to estimate the respective effects of GA and GG. 122 
However, the estimated effects were similar for GG & GA, and when combined the model 123 
goodness of fit was not affected. Using the principle of parsimony, we decided to use the 124 
simpler model, as the effects of GG and GA were not statistically significant. The other 125 
pharmacogenetic variants did not affect the pharmacokinetic parameters. 126 
Patients infected with HIV infection were found to have 21.9% lower bioavailability (ΔOFV 127 
42, p<0.001). The patients who were treated with high 1200 mg doses of rifapentine tended 128 
to have clearance reduced by 13.2% compared to other dose groups (ΔOFV 17, p<0.001). 129 
The pharmacokinetic differences between the two studies were explored and it was found that 130 
the bioavailability of rifapentine in the Daily RPE study was 23.3% lower than in the 131 
RIFAQUIN study (Δ OFV 59, p<0.001). The pharmacogenetic covariates other than AADAC 132 
rs1803155 polymorphism didn’t have significant effects on the pharmacokinetic parameters. 133 
DISCUSSION 134 
The present study is the first to investigate the influence of various plausible physiologically-135 
relevant candidate gene polymorphisms on rifapentine pharmacokinetics. We developed a 136 
population pharmacokinetic model of rifapentine, which was consistent with previous reports, 137 
and tested the effect of genotype information on the pharmacokinetic parameters. We showed 138 
that the AADAC rs1803155 polymorphism is associated with rifapentine clearance. Subjects 139 
carrying the AA genotype had 10.4% lower clearance than those carrying AG or GG, thus 140 
leading to increased rifapentine exposure. The low clearance due to this polymorphism is 141 
consistent with previous studies reporting decreased activity of AADAC activity due to the 142 
presence of the variant allele (19). The majority of patients in our study had the AADAC 143 
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rs1803155 AA variant allele which occurred at a frequency of 0.82, and 65% were 144 
homozygous for the single nucleotide polymorphism, which could, in part, account for the 145 
relatively high rifapentine exposures described. The polymorphism occurs at lower 146 
frequencies of 0.50 to 0.64 in European American, African American, Korean, and Japanese 147 
populations (19). Another study identified lower rifapentine concentrations in black Africans 148 
but the influence of pharmacogenetic factors, which might account for the difference in the 149 
genotype frequencies between the populations, was not explored (20), whereas Sloan et al., 150 
who explored the influence of AADAC gene polymorphisms on rifampicin pharmacokinetics 151 
in Malawian patients, did not identify a significant relationship (21).The prevalence of variant 152 
genotypes is different between African ethnic groups and may be the reason for this 153 
contrasting effect. As only 3 of 162 patients had rs1803155 GG, no meaningful separate 154 
estimate of clearance for this genotype could be obtained.   In further attempts to explain 155 
variability in rifapentine pharmacokinetics, we explored the effects of several polymorphisms 156 
of drug transporters and transcriptional regulators. The choice of polymorphisms was based 157 
on those previously described to affect drug disposition, and also by previous 158 
pharmacogenetic studies conducted on rifampicin. Interestingly, we could not detect the 159 
effect SLCO1B1 rs4149032 polymorphism on pharmacokinetics of rifapentine, even with a 160 
carrier, no carrier approach. The frequency of SLCO1B1 in our cohort was 0.75, which is in 161 
agreement with previous finding in South African patients from the Cape Town region. 162 
Similarly, we did not find a statistically significant effect associated with SLCO1B1 163 
rs2306283, which existed in our study population at a frequency of 0.82. SLCO1B1 164 
polymorphisms have been reported to be associated with low rifampicin levels (13,14) and 165 
the lack of effect on rifapentine may suggest differences in the ADME of the two drugs. It 166 
may be that this transporter does not play a major role in the pharmacokinetics of rifapentine, 167 
or that the variant allele is associated with greater induction by rifampicin. We did not 168 
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observe an effect due to polymorphisms of the transcriptional regulators. This could be due to 169 
activation of PXR or CAR by rifapentine, which may have overridden any constitutive 170 
effects.  171 
Additionally, we found that HIV infected patients have lower bioavailability of rifapentine. 172 
While the association of HIV infection with antituberculosis drug exposures is inconsistent, 173 
our findings for rifapentine are consistent with recent studies (22-24). The data available was 174 
not sufficient to identify potential drug-drug interactions with the various antiretroviral drugs 175 
prescribed concomitantly.  176 
Patients in the higher dose group (1200 mg given once weekly) had increased exposure in the 177 
current study contrary to the findings by Savic et al., which describes a decrease in the 178 
bioavailability of rifapentine with increased dose (6). The reduced dosing frequency in this 179 
group, may have led to reduced auto-induction and thus increased exposure.   180 
Previous reports demonstrate that exposure to rifamycins is reduced in males due to a higher 181 
FFM: body weight ratio (25). The study by Langdon et al. described a 35% reduction in the 182 
clearance of 25-desacetyl rifapentine amongst females (5). In the present analysis, as 183 
allometric scaling with FFM   accounted for the variability associated with sex, we did not 184 
observe any outstanding effects of sex. There was a difference in bioavailability between the 185 
two studies included in this analysis. This may be due to differences in food intake with the 186 
dose. Rifapentine absorption is strongly enhanced when it is administered with food (7). The 187 
finding that the Daily RPE study had a lower bioavailability may arise from the fact that 188 
meals with the dose were not standardized, in contrast to the RIFAQUIN study where a 189 
standard meal was provided throughout the study.  190 
To conclude, our study is the first to show that the AADAC rs1803155 (AA) genotype is 191 
associated with lower rifapentine clearance, leading to increased rifapentine exposure. This 192 
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effect should be confirmed in a larger independent analysis. The pharmacogenetic association 193 
was modest compared to the study effect, which is likely linked to differences in the pattern 194 
of food use across the studies and highlights the importance of food recommendations both 195 
when the drug is used in a programmatic setting and when its pharmacokinetics is 196 
investigated.   Additionally, we found that rifapentine exposure was lower in HIV infected 197 
patients, a finding consistent with previous studies and warranting further investigation to 198 
assess whether dose adjustment strategies should be considered. Lastly, patients dosed with 199 
1200 mg once weekly doses had lower clearance, possibly as a result of less pronounced 200 
autoinduction.  201 
 202 
MATERIALS AND METHODS 203 
Study population: This analysis was performed on patients diagnosed with pulmonary TB 204 
from two clinical studies: The Phase III RIFAQUIN study (ISRCTN44153044) (26) and two-205 
stage activity-safety study of daily rifapentine (27), hereinafter “Daily RPE” 206 
(NCT00814671). A subset of participants from these studies provided their consent to assess 207 
the effect of genetic polymorphisms of nuclear receptors, drug metabolizing enzymes, and 208 
drug transporters on the pharmacokinetics of rifapentine.  209 
The RIFAQUIN study included two experimental arms in which patients were dosed with 210 
daily moxifloxacin, rifampicin, pyrazinamide, and ethambutol for 2 months followed by a 211 
continuation phase with either 4 months of once weekly 1200 mg rifapentine together with 212 
400 mg moxifloxacin, or 2 months of 400 mg moxifloxacin twice weekly with 900 mg of 213 
rifapentine. The RIFAQUIN study was conducted at sites in the Western Cape and Gauteng 214 
regions of South Africa and in Harare, Zimbabwe. The doses of rifapentine and moxifloxacin 215 
were taken with 240 mL of water 15 minutes after a light meal of 2 hard-boiled eggs with 216 
 o
n
 January 25, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
10 
 
bread. During the 4
th
 month of treatment, blood samples were drawn for determination of 217 
plasma rifapentine concentrations. The pharmacokinetic assessment involved rich (with a 218 
pre-dose and samples at 1, 2, 3, 5, 7, 10, 12, 26, and 50 h after dosing) or sparse sampling 219 
(samples drawn around 2, 5, and 24 or 48 h after dosing). 220 
The Daily RPE study was open-label and had two experimental arms. Patients with 221 
pulmonary tuberculosis were randomized to 450 or 600 mg rifapentine daily, which replaced 222 
600 mg rifampicin during the intensive phase of standard therapy. The study participants 223 
were recruited in the Western Cape, South Africa. The patients were advised to take the 224 
required Rifapentine dose with food, but no standardised meal was provided during the study 225 
and no accurate details about food intake with the dose were recorded. Pharmacokinetic 226 
sampling was performed at approximately one month after starting therapy and samples were 227 
obtained either with intensive (with samples pre-dose and at 0.75, 1.5, 3.5, 5, 12, and 24 h 228 
after dose), or sparse sampling (0.5-2 h and 5-8 h after dose). Separate written informed 229 
consent for the pharmacogenetic study was obtained from participants retrospectively. The 230 
pharmacogenetic study was reviewed and approved the Research Ethics Committee of the 231 
University of Cape Town and the University of the Witwatersrand. 232 
Drug determination: Plasma rifapentine concentrations were determined with a validated 233 
liquid chromatography-tandem mass spectrometry assay developed in the Division of Clinical 234 
Pharmacology, University of Cape Town. Samples were processed with a protein 235 
precipitation extraction method using rifaximin as internal standard, followed by high 236 
performance liquid chromatography with MS/MS detection using an AB SCIEX API 3200 237 
instrument. The analyte and internal standard were monitored at mass transitions of the 238 
protonated precursor ions m/z 877.3 and m/z 786.3 to the product ions m/z 845.4 and m/z 239 
754.1 for rifapentine and rifaximin, respectively. The calibration curves fit quadratic 240 
(weighted by 1/concentration) regressions over the ranges 0.156 – 40.0 mg/L for rifapentine. 241 
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The accuracies for the rifapentine assay were 103.9%, 102.8%, and 97.5% at the low, 242 
medium, and high QC levels, respectively, during inter-batch validation. The lower limit of 243 
quantification (LLOQ) was 0.156 mg/L.  244 
SNP genotyping: Genomic DNA was extracted from 200 µL whole blood using QIAamp 245 
DNA Mini Kit (Qiagen, Inc., Valencia, California) in accordance with the manufacturer’s 246 
protocol. DNA was quantified spectrophotometrically using NanoDrop (Thermo Fisher 247 
Scientific Inc., Wilmington, Delaware) before storage at −20°C. Genotyping was performed 248 
by real-time polymerase chain reaction (PCR) on a DNA Engine Chromo4 system (Bio-Rad 249 
Laboratories, Inc., Hercules, California). The PCR protocol involved an initial denaturation 250 
step at 95°C for 15 min, followed by 50 cycles of amplification at 95°C for 15 s and final 251 
annealing at 60°C for 1 min. TaqMan Genotyping Master Mix and assays for SLCO1B1 252 
rs2306283 (SNP ID: C_1901697_20), SLCO1B1 rs4149032 (C_1901709_10), NR1I2 253 
rs2472677 (C_26079845_10), NR1I2 rs1523130 (C_9152783_20), and AADAC rs1803155 254 
(C_8911003_1_) were obtained from Thermo Fisher Scientific (Waltham, Massachusetts). 255 
Allelic discrimination plots and genotype assignments were performed using Opticon 256 
Monitor, version 3.1 from Bio-Rad Laboratories.  257 
Pharmacokinetic analysis: Rifapentine plasma concentration-time data was analysed using a 258 
nonlinear mixed-effects model implemented in NONMEM 7.4.2 (28). The execution of runs 259 
was through Perl-speaks-NONMEM, Pirana and graphical diagnostics were created using 260 
Xpose 4.6.0 and R (29,30). Estimation of typical population pharmacokinetic parameters, 261 
along with their random inter-individual (IIV) and inter-occasion (IOV) variability was 262 
performed using first-order conditional estimation method with ε-η interaction (FOCE 263 
INTER). A lognormal distribution was assumed for IIV and IOV and a combined additive 264 
and proportional model for the residual unexplained variability (RUV) was evaluated. 265 
Various structural models were tested including one or two-compartment distribution with 266 
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first-order elimination and first–order absorption with or without lag time or transit 267 
compartment absorption (31). The influence of genetic polymorphisms on rifapentine 268 
pharmacokinetics for patients with unknown genotype was identified using mixture 269 
modelling (32). The effect of the genotype was first tested using method EXTRA which 270 
estimates the association only for the patients with available genetic information but also 271 
estimating an additional covariate effect for the unknown genotype. Subsequently, the MIX 272 
method to impute values using mixture modelling was applied to include the patient with 273 
unknown genotype to strengthen the robustness of the findings (32). Model selection was 274 
based on changes in the NONMEM objective function value (ΔOFV), and visual inspection 275 
of conditional weighted residuals (CWRES) versus time, visual predictive checks (33), and 276 
basic goodness of fit plots (GOF). During model development, physiological plausibility and 277 
the precision of the parameter estimates were also considered. The model parameters of the 278 
final model were evaluated for their precision using sampling importance resampling method 279 
(SIR) (34). 280 
Allometric scaling was applied on clearance (CL), and volume of distribution (V) to adjust 281 
for the effect of body size, according to Anderson and Holford (35). Fat-free mass (FFM), 282 
and fat mass (FAT) were tested as alternative size predictors through allometric scaling 283 
instead of total body weight (35,36). After the inclusion of allometric scaling, potential 284 
demographic, study site specific and pharmacogenetic covariates were screened inspecting 285 
parameter versus covariate plots and then tested in the model using drops in objective 286 
function value (assumed to be χ-square distributed and thus using 3.84 points drop as 287 
significant at p<0.05 for the inclusion of a single parameter), while scrutinising the 288 
physiological plausibility of the effect (37). 289 
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 431 
Table 1: Demographic and clinical characteristics of patients 432 
Demographic 
& Clinical 
Characteristics 
Daily RPE 
450 mg 
group 
(N=44) 
Daily RPE 
600 mg 
group 
(N=41) 
RIFAQUIN 
900 mg 
group 
(N=116) 
RIFAQUIN 
1200 mg 
group 
(N=125) 
Overall 
(N=326) 
No. of PK 
samples 
166 130 416 432 1144 
Sex 
(male/female) 
(33/11) (32/9) (72/44) (81/44) (218/108) 
Number of 
HIV+ patients 
6 (13.6%) 7 (17.1%) 30 (25.9%) 16(12.8%) 59(18.1%) 
Median age, 
range (yrs) 
29 (19-61) 29 (18-63) 31 (19-64) 34 (19- 80) 32 (18-80) 
Median 
weight in kg 
(range)  
55 (45-79) 55 (45-94) 55 (38-77) 57 (38- 78) 56 (38-94) 
Median FFM 
in kg (range) 
47 (32-58) 47 (32-56) 45 (27-62) 45 (27-60) 45 (27-62) 
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 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
Table 2: Observed genotype and allele frequency of Single nucleotide polymorphisms in the 442 
study (N=162) 443 
Genotype Genotype frequency (%) Allele frequencies  
SLCO1B1 A>G 
rs2306283 
AA AG GG A G 
8 (4.94) 43 (26.5) 111 (68.5) 0.18 0.82 
SLCO1B1 C>T 
rs4149032 
CC CT TT C T 
15 (9.26) 52 (32.1) 95 (58.6) 0.25 0.75 
*NR1I2 C>T 
rs2472677 
CC CT TT C T 
71 (44.1) 72(44.7) 18 (11.2) 0.67 0.34 
NR1I2 T>C 
rs1523130 
TT CT CC T C 
116 (71.6) 39 (24.1) 7 (4.3) 0.84 0.16 
AADAC G>A 
rs1803155 
GG GA AA G A 
3 (1.85) 53 (32.7) 106 (65.4) 0.18 0.82 
*The data available only for 161 patients 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
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 459 
 460 
Table 3: Final parameter estimates for rifapentine population pharmacokinetic model 461 
Parameter 
Estimate  
 
95% CI IIV
+
 or IOV
++
 95% CI 
CL
a
 (L/hr) 1.33 1.14;1.54 23.0%
+
  17.7;28.6 
V
a
 (L) 25  21.9;28.4 12.8%
+
  8.8;17.4 
ka (hr
-1
) 0.814 0.568;1.26 48.9%
++
  36.4;59.8 
MTT (hr) 1.47  1.20;1.78 37.4%
++
  28.3;48.6 
NN 10.2  6.70;14.0 - - 
F 1 FIXED  20.3%
++
  14.9;26.4 
Proportional residual error 
(%) 
9.56 7.09;13.2 - - 
Additive residual error 
(mg/L) 
0.247  0.143-0.401 - - 
HIV+ effect on F (%) -21.9  -33.2; -6.64 - - 
Group on 1200 mg dose in 
RIFAQUIN study on CL (%) 
-13.2 -22.8; -4.36 - - 
Daily RPE study on F (%) -23.3  -35.6: -9.25 - - 
AADAC rs1803155 (AA) 
effect on CL (%) 
-10.4 -17.3; -3.53 - - 
CL-oral clearance; V-apparent volume of distribution in the central compartment; ka-first-462 
order absorption rate constant; MTT- absorption mean transit time; NN- number of 463 
hypothetical transit compartments; F- oral bioavailability; HIV+ - Human immunodeficiency 464 
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virus positive; AADAC- arylacetamide deacetylase.  IIV- inter-individual variability, and 465 
IOV- inter-occasional variability are expressed as percent coefficient of variation (% CV). 466 
 a
 - 
The typical values of clearance and volume of distribution reported for a patient with body 467 
weight 56 kg and FFM of 46 kg.  468 
95% CI of parameter estimates obtained with Sampling importance resampling (SIR) n=1000 469 
of the final model. 470 
 471 
 472 
Figure 1: Visual predictive check (VPC) for the final rifapentine population pharmacokinetic 473 
model in log scale, stratified according to different dose groups in the analysis.  474 
The lower, middle, and upper solid lines are the 2.5
th
, 50
th
, and 97.5
th
 percentiles of the 475 
observed plasma concentration. The shaded areas are the 95% confidence intervals for the 476 
same percentiles, obtained from re-simulations of the same trial. 477 
 478 
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